Ebo Didier G, Beyens Michiel, Heremans Kevin, van der Poorten Marie-Line M, Van Gasse Athina L, Mertens Christel, Houdt Michel Van, Sabato Vito, Elst Jessy
Department of Immunology, Allergology and Rheumatology and the Infla-Med Centre of Excellence, University Antwerp, Antwerp University Hospital, Antwerpen, Belgium.
Department of Immunology and Allergology, AZ Jan Palfijn Gent, Ghent, Belgium.
Curr Pharm Des. 2023;29(3):178-184. doi: 10.2174/1381612829666221025091827.
Immediate hypersensitivity reactions can pose a clinical and diagnostic challenge, mainly because of the multifarious clinical presentation and distinct underlying - frequently uncertain - mechanisms. Anaphylaxis encompasses all rapidly developing and life-threatening signs and may cause death. Evidence has accumulated that immediate hypersensitivity and anaphylaxis do not necessarily involve an allergen-specific immune response with cross-linking of specific IgE (sIgE) antibodies bound to their high-affinity IgE receptor (FcεRI) on the surface of mast cells (MCs) and basophils. Immediate hypersensitivity and anaphylaxis can also result from alternative specific and nonspecific MC and basophils activation and degranulation, such as complementderived anaphylatoxins and off-target occupancy of MC and/or basophil surface receptors such as the Masrelated G protein-coupled receptor X2 (MRGPRX2). Degranulation of MCs and basophils results in the release of inflammatory mediators, which can be, depending on the underlying trigger, in a different spatiotemporal manner. In addition, hypersensitivity and anaphylaxis can occur entirely independently of MC and basophil degranulation, as observed in hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs) that divert normal arachidonic acid metabolism by inhibiting the cyclooxygenase (COX)-1 isoenzyme. Finally, one should remember that anaphylaxis might be part of the phenotype of particular - sometimes poorly recognizable - conditions such as clonal MC diseases (e.g. mastocytosis) and MC activation syndrome. This review provides a status update on the molecular mechanisms involved in both sIgE/FcεRI- and non-sIgE/FcεRI-dependent immediate hypersensitivity and anaphylaxis. In conclusion, there is increasing evidence for alternative pathophysiological hypersensitivity and anaphylaxis endotypes that are phenotypically and biologically indistinguishable, which are frequently difficult to diagnose, mainly because of uncertainties associated with diagnostic tests that might not enable to unveil the underlying mechanism.
速发型超敏反应会带来临床和诊断方面的挑战,主要原因是其临床表现多样,且潜在机制各异——通常还不明确。过敏反应涵盖所有迅速出现且危及生命的体征,可能导致死亡。已有证据表明,速发型超敏反应和过敏反应不一定涉及过敏原特异性免疫反应,即与肥大细胞(MC)和嗜碱性粒细胞表面高亲和力IgE受体(FcεRI)结合的特异性IgE(sIgE)抗体发生交联。速发型超敏反应和过敏反应也可能由其他特异性和非特异性的MC及嗜碱性粒细胞激活和脱颗粒引起,比如补体衍生的过敏毒素以及MC和/或嗜碱性粒细胞表面受体(如Mas相关G蛋白偶联受体X2,MRGPRX2)的非靶向占据。MC和嗜碱性粒细胞的脱颗粒会导致炎症介质的释放,根据潜在触发因素的不同,其释放方式在时空上也会有所不同。此外,超敏反应和过敏反应可能完全独立于MC和嗜碱性粒细胞的脱颗粒而发生,如在对非甾体抗炎药(NSAIDs)过敏的情况中,NSAIDs通过抑制环氧化酶(COX)-1同工酶使正常的花生四烯酸代谢发生改变。最后,应记住过敏反应可能是某些特殊情况(有时难以识别)的表型的一部分,如克隆性MC疾病(如肥大细胞增多症)和MC激活综合征。本综述提供了关于sIgE/FcεRI依赖性和非sIgE/FcεRI依赖性速发型超敏反应及过敏反应所涉及分子机制的最新情况。总之,越来越多的证据表明存在替代的病理生理超敏反应和过敏反应亚型,它们在表型和生物学上难以区分,通常难以诊断,主要是因为诊断测试存在不确定性,可能无法揭示潜在机制。